⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KALV News
KalVista Pharmaceuticals, Inc. Common Stock
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
KALV
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY ® (sebetralstat)
businesswire.com
KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
businesswire.com
KALV
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
businesswire.com
KALV
KalVista Pharmaceuticals to Present EKTERLY ® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
businesswire.com
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
KALV
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
businesswire.com
KALV
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
businesswire.com
KALV
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
prnewswire.com
NTLA
ASTX
RZLT
IONS
KALV
BCRX
TAK
KAVL
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
businesswire.com
KALV